CD163 as a Potential Biomarker of Monocyte Activation in Ischemic Stroke Patients

Area of Science:

• Immunology
• Neurology
• Biochemistry

Background:

• Elevated monocyte counts in ischemic stroke patients are linked to disease severity and poorer outcomes.
• Understanding monocyte subpopulation roles is crucial for clarifying their complex functions and impact in stroke.

Purpose of the Study:

• To investigate the subtype-specific distribution of CD163+ and CD80+ circulating monocytes post-ischemic stroke.
• To evaluate the association between these monocyte subpopulations and the inflammatory status in stroke patients.

Main Methods:

• Flow cytometry was used to analyze CD163+ and CD80+ monocyte subpopulations.
• Gene expression analysis (mRNA) was performed on total monocytes for inflammatory markers.
• Patient samples were collected 24 and 48 hours after stroke, compared to healthy controls.

Main Results:

• Increased CD163+/CD16+ and CD163+/CD14++ monocyte events were observed 24 and 48 hours post-stroke.
• CD163+ expression was higher in CD16+ non-classical and intermediate monocytes 24 hours after stroke.
• Elevated IL-1beta, TNF-alpha, and IL-4 mRNA, with reduced IL-10 mRNA, were found in patient monocytes.
• The percentage of CD163+/CD16+ events correlated positively with NIHSS score and mRS, indicating a link to stroke severity.

Conclusions:

• CD163+ expression in CD16+ monocytes increases post-ischemic stroke and is associated with stroke severity.
• Monocyte subpopulation dynamics and inflammatory profiles offer insights into stroke pathophysiology.
• CD163+ monocytes may serve as potential biomarkers for stroke severity and prognosis.